Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Ipsen

Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U.
From Ipsen
Via Business Wire
Tickers IPSEY OTC
Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI
From Ipsen
Via Business Wire
Tickers IPSEY OTC
Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases
From Ipsen
Via Business Wire
Tickers IPSEY OTC
Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva
From Ipsen
Via Business Wire
Tickers IPSEY OTC
Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy
From Ipsen
Via Business Wire
Tickers IPSEY OTC
Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
From Ipsen
Via Business Wire
Tickers IPSEY OTC
Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance
From Ipsen
Via Business Wire
Tickers IPSEY OTC
Ipsen Statement on Updated Timeline for Palovarotene FDA Advisory Committee Meeting
From Ipsen
Via Business Wire
Tickers IPSEY OTC
Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology
From Ipsen
Via Business Wire
Tickers IPSEY OTC
Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022
From Ipsen
Via Business Wire
Tickers IPSEY OTC
Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer
From Ipsen
Via Business Wire
Tickers IPSEY OTC
Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates From Marengo’s STAR Platform Into the Clinic
From Ipsen
Via Business Wire
Tickers IPSEY OTC
Ipsen Delivers Strong H1 2022 Results and Upgrades Its Full-Year Guidance
From Ipsen
Via Business Wire
Tickers IPSEY OTC
Ipsen Announces U.S. FDA Priority Review for palovarotene New Drug Application in Patients With Fibrodysplasia Ossificans Progressiva Following Resubmission
From Ipsen
Via Business Wire
Tickers IPSEY OTC
Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults With Neurogenic Detrusor Overactivity Due to Multiple Sclerosis or Spinal Cord Injury
From Ipsen
Via Business Wire
Tickers IPSEY OTC
Ipsen: ASCO 2022: New Cabometyx® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer
From Ipsen
Via Business Wire
Tickers IPSEY OTC
Ipsen: European Commission Approves Cabometyx® as a Second-Line Treatment for People Living With Radioactive Iodine-Refractory Differentiated Thyroid Cancer
From Ipsen
Via Business Wire
Tickers IPSEY OTC
Ipsen Delivers a Strong Sales Performance in the First Quarter Of 2022
From Ipsen
Via Business Wire
Tickers IPSEY OTC
Ipsen Receives Positive CHMP Opinion for Cabometyx® in Radioactive Iodine-refractory Differentiated Thyroid Cancer
From Ipsen
Via Business Wire
Tickers OTC
Ipsen Announces Investment in New State-of-the-Art Electronic Autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) Designed to Improve Patient Experience
From Ipsen
Via Business Wire
Tickers OTC
Ipsen: Cabometyx® in Combination With Opdivo® Demonstrated Continued Survival and Quality of Life Benefits With Over Two Years of Follow-Up in the Phase III CheckMate -9ER Trial
From Ipsen
Via Business Wire
Tickers OTC
Ipsen Presents Strong Full-Year 2021 Results and Enters Into Exclusive Negotiations to Divest Its Consumer Healthcare Business
From Ipsen
Via Business Wire
Tickers OTC
Health Canada Approves Ipsen’s Sohonos™ (palovarotene capsules) as the First Approved Treatment for Fibrodysplasia Ossificans Progressiva
From Ipsen
Via Business Wire
Tickers OTC
Ipsen Nominates Karen Witts as New Independent Board Member
From Ipsen
Via Business Wire
Tickers OTC
Ipsen Appoints Stewart Campbell Executive Vice President and President of North America
From Ipsen
Via Business Wire
Tickers OTC
Ipsen Pledges Ambitious Action on Climate Change
From Ipsen
Via Business Wire
Tickers OTC
Ipsen Delivers Strong Sales Growth for the First Nine Months and Improves Its Full-Year Guidance
From Ipsen
Via Business Wire
Tickers OTC
Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3
From Ipsen
Via Business Wire
Tickers OTC
Ipsen appoints Mari Scheiffele as EVP and President, Specialty Care International
From Ipsen
Via Business Wire
Tickers OTC
Ipsen: ESMO 2021: Cabometyx® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer
From Ipsen
Via Business Wire
Tickers OTC
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.